MIRA
INFORM REPORT
|
Report Date : |
03.01.2008 |
IDENTIFICATION
DETAILS
|
Name : |
RUSAN PHARMA LIMITED |
|
|
|
|
Registered Office : |
Rusan House, 58-D, Government Industrial Estate, Charkop, Kandavli (West), Mumbai – 400 067, Maharashtra |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2006 |
|
|
|
|
Date of Incorporation : |
15.03.1994 |
|
|
|
|
Com. Reg. No.: |
077069 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24230MH1994PLC077069 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
MUMR14490A |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AABCR3179H |
|
|
|
|
Legal Form : |
A Closely Held Public Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer and Exporter of pharmaceutical formulations, bulk drugs and intermediates |
RATING &
COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
Maximum Credit Limit : |
USD 1040156 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and reputed company having satisfactory track. Directors are reported as experienced and respectable businessmen. Trade relations are fair. Business is active. Payments are reported as usually correct and as per commitments The company can be considered normal for business dealings at usual trade terms and conditions. |
LOCATIONS
|
Registered Office : |
Rusan House, 58-D, Government Industrial Estate, Charkop, Kandivli (West), Mumbai – 400 067, Maharashtra |
|
Tel. No.: |
91-22-28682512 |
|
Fax No.: |
91-22-28689056 |
|
E-Mail : |
|
|
|
|
|
Bulk Drug Plant/Factory : |
Plot No. 6406, GIDC, Ankleshwar, District Bharuch, Gujarat |
|
|
|
|
Formulation Unit: (Kandla Division): |
Plot No. 59 to 65, Sector II, Kandla Special Economic Zone, Gandhidham, Kutch, Gujarat – 370230 |
|
|
|
|
Branches/ : |
703, 2nd Floor, GIDC Industrial Estate, Road No. 56, Baroda – 390 010, Gujarat |
DIRECTORS
|
Name : |
Mr. Navin Satyapal Saxena |
|
Designation : |
Director |
|
Address : |
Sea Castle Co-operative Housing Society, 301, 7 Bunglow Road, Versova, Andheri (West), Mumbai – 400 061 |
|
Date of Birth/Age : |
01.01.1953 |
|
Date of Appointment : |
15.03.1994 |
|
|
|
|
Name : |
Mr. Ramesh A. Patel |
|
Designation : |
Director |
|
Address : |
B/8, Bhavana Building, S. V. Road, Kandivli (West), Mumbai – 400 067 |
|
Date of Birth/Age : |
05.12.1939 |
|
Date of Appointment : |
02.05.1995 |
|
|
|
|
Name : |
Mr. Dilipkumar Khandbhai Desai |
|
Designation : |
Director |
|
Address : |
D – 67, Gordhan Baug, Jambli Galli, Borivali (W), Mumbai – 400092,
Maharashtra, India |
|
Date of Birth/Age : |
06.05.1948 |
|
Date of Appointment : |
21.04.1998 |
|
|
|
|
Name : |
Mr. Pradipkumar N. Shah |
|
Designation : |
Director (Resign on 25.04.2001) |
|
Address : |
A/7, West View Building No. 2, S. V. Road, Santacruz (West), Mumbai – 400 054 |
|
Date of Birth/Age : |
31.07.1938 |
|
Date of Appointment : |
02.05.1995 |
KEY EXECUTIVES
|
Name : |
V. I. Desai and Company |
|
Designation : |
Company Secretary |
|
Address : |
Mumbai - 400057 |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
|
Names of Shareholders |
|
No. of Shares |
|
|
|
|
|
Mr. Navin Satyapal Saxena |
|
728184 |
|
Mrs. Archana Navin Saxena |
|
239974 |
|
Mr. Dilip Khandubhai Desai |
|
10 |
|
Mrs. Usha Dilip Desai |
|
10 |
|
Mr. Pradip Nanalal Shah |
|
10 |
|
Mrs. Shakuntala Ramesh Patel |
|
10 |
|
Mr. Ramesh Ambalal Patel |
|
10 |
|
|
|
|
|
Total |
|
968208 |
|
|
|
|
|
Category |
|
Percentage |
|
Directors or relatives of directors |
|
100.00 |
|
|
|
|
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Exporter of pharmaceutical formulations, bulk drugs and intermediates |
||||||||||
|
|
|
||||||||||
|
Products : |
|
||||||||||
|
|
|
PRODUCTION STATUS
|
Particulars |
Unit |
Licensed
Capacity |
Installed
Capacity |
Actual
Production |
|
Tablets |
No. |
375 |
375 |
345.010 |
|
Capsules |
No. |
225 |
155 |
-- |
|
Dry Syrup |
No. |
7.50 |
7.50 |
57.80 |
|
Injections / Vials |
Ltr. |
15 |
15 |
-- |
|
Injections / Ampoules |
Ltr. |
15 |
09 |
-- |
|
Injectibles |
Bottle |
-- |
-- |
-- |
|
Drops |
Ltr. |
-- |
-- |
-- |
|
Liquids |
Ltr. |
-- |
-- |
|
|
Creams |
Kgs. |
-- |
-- |
3241.50 |
|
Bulk Drugs |
Kgs. |
-- |
-- |
282.75 |
|
Buprenorphine Hydrochloride |
Kgs. |
-- |
60 |
-- |
|
Tramadol Hydrochloride |
Kgs. |
-- |
1500 |
-- |
|
Bisoprolol Fumerate |
Kgs. |
-- |
25 |
-- |
|
Fantany |
Kgs. |
-- |
30 |
-- |
|
Naltraxone |
Kgs. |
-- |
50 |
-- |
GENERAL
INFORMATION
|
Customers: |
· Rusan Helathcare Private Limited · Pharmacare FZE |
||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||
|
No. of Employees : |
600 |
||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||
|
Bankers : |
· Canara Bank, Overseas Branch, Nariman Point, Mumbai – 400 021 · Indian Bank · State Bank of India · State Bank of Indore · Swami Narayan Bank |
||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
Good |
|
|
|
|
Auditors : |
|
|
Name : |
P. P. Shah and Associates Chartered Accountants |
|
Address : |
5B-1, Fairy Manor, 13, Rustom Sidhwa Marg (Gunbow Street), Fort, Mumbai – 400 001, Maharashtra, India |
|
Tel. No.: |
91-22-22673482 / 83 |
|
Fax No.: |
91-22-22673321 |
|
E-Mail : |
|
|
|
|
|
Associates/Subsidiaries : |
|
|
|
· Q-Tech Research Lab Private Limited ·
Tuscany Holdings Private Limited U65990MH1994PTC081494 · Tuscany Holding Private Limited · Navin Saxena Res and Technology Private Limited ·
Tulip Trading Company ·
Rusan Healthcare Private Limited ·
Pharmacare FZE ·
Dr. Navin Saxena ·
Mrs. Archana Saxena ·
Mr. D K Desai · Mr. R A Patel |
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
1000000 |
Equity Shares |
Rs. 10/- each |
Rs. 10.000 millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
968208 |
Equity Shares |
Rs. 10/- each |
Rs. 9.682 millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
9.682 |
9.682 |
9.682 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
250.357 |
228.778 |
214.049 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
260.039 |
238.460 |
223.731 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
66.128 |
52.477 |
63.867 |
|
|
2] Unsecured Loans |
13.449 |
40.322 |
39.818 |
|
|
TOTAL BORROWING |
79.577 |
92.799 |
103.685 |
|
|
DEFERRED TAX LIABILITIES |
0.218 |
1.301 |
1.059 |
|
|
|
|
|
|
|
|
TOTAL |
339.834 |
332.560 |
328.475 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
115.809 |
119.150 |
119.332 |
|
|
Capital work-in-progress |
2.566 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
15.288 |
14.789 |
14.789 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
67.674
|
49.563 |
48.913 |
|
|
Sundry Debtors |
196.485
|
170.591 |
184.679 |
|
|
Cash & Bank Balances |
13.027
|
18.194 |
18.185 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
41.642
|
38.537 |
36.542 |
|
Total
Current Assets |
318.828
|
276.885 |
288.319 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
111.371
|
80.145 |
96.794 |
|
|
Provisions |
3.510
|
2.760 |
4.230 |
|
Total
Current Liabilities |
114.881
|
82.905 |
101.024 |
|
|
Net Current Assets |
203.947
|
193.980 |
187.295 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
2.224 |
4.641 |
7.059 |
|
|
|
|
|
|
|
|
TOTAL |
339.834 |
332.560 |
328.475 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
|
Sales Turnover |
297.249 |
311.220 |
288.946 |
|
|
Other Income |
3.913 |
2.818 |
0.000 |
|
|
Total Income |
301.162 |
314.038 |
288.946 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
25.963 |
18.019 |
39.280 |
|
|
Provision for Taxation |
(0.333) |
0.243 |
1.499 |
|
|
Profit/(Loss) After Tax |
26.296 |
17.776 |
37.781 |
|
|
|
|
|
|
|
|
Export Value |
N.A. |
N.A. |
N.A. |
|
|
|
|
|
|
|
|
Import Value |
N.A. |
13.181 |
15.587 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Raw Material Consumed |
77.994 |
114.934 |
145.603 |
|
|
Purchases made for re-sale |
13.615 |
2.491 |
14.090 |
|
|
Increase/(Decrease) in Finished Goods |
(8.745) |
1.302 |
24.959 |
|
|
Salaries, Wages, Bonus, etc. |
2.630 |
24.384 |
25.585 |
|
|
Managerial Remuneration |
1.418 |
1.280 |
7.509 |
|
|
Payment to Auditors |
0.725 |
0.888 |
13.158 |
|
|
Interest |
6.439 |
5.425 |
2.417 |
|
|
Insurance Expenses |
1.017 |
0.910 |
0.000 |
|
|
Power & Fuel |
8.456 |
10.411 |
0.000 |
|
|
Depreciation & Amortization |
16.822 |
16.275 |
16.345 |
|
|
Other Expenditure |
154.827 |
117.713 |
0.000 |
|
Total Expenditure |
275.198 |
296.018 |
249.666 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2006 |
31.03.2005 |
31.03.2004 |
|
PAT / Total Income |
(%) |
8.73
|
5.66 |
13.07 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
8.73
|
5.79 |
13.59 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
5.97
|
4.55 |
9.63 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.10
|
0.07 |
0.17 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
0.75
|
0.74 |
0.91 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.77
|
3.34 |
2.85 |
LOCAL AGENCY
FURTHER INFORMATION
Fixed Assets
· Land
· Factory Building
· Plant and Machinery
· Office Equipments
· Equipments and Tools for R and D
· Dies
· Air condition
· Electric Installation
· Furniture and Fixture
· Computer
· Vehicles
· Guest House Equipments
Business:
The company manufactures and markets a wide range of formulations in various conventional and technologically advanced dosage forms.
Generic Names of the Principal Products of the company are :
· Pyrazinamide
· Buprenorphine Hydrochloride
· Paracetamol
With the establishment of Rusan Research Centre in Mumbai, the company is rapidly emerging as a research driven enterprise with a sharply focused vision and well-defined goals.
The company’s manufacturing plant with an area of 28000 sq.mtrs. is located in the Kandla Special Economic Zone (previously Kandla Free Trade Zone).
The company has established a sophisticated bulk drug manufacturing facility plant at 6406, GIDC, Ankleshwar for bulk drugs and intermediates with facilities for lab scale and scale up. This multipurpose plant with an area 2000 sq.mtrs. has been designed to meet US FDA requirements. At present, the manpower at Ankleshwar includes 5 technical personnel and 10 skilled labours.
The company’s products are registered in the following countries :
· Russian Federation
· Ukraine
· Uzbekistan
· Kazakistan
· Azerbizan
· Mynmar
Its’ products will soon be registered in the following countries :
· Vietnam
· Uganda
· Iraq
· Tanzania
· Sri Lanka
· Sudan
· Phillipines
· Cambodia
· Kenya
· Libya
· Nepal
The company’s fixed assets of important value include land – Ankleshwar, factory building, plant & machinery, office equipments, furniture & fixtures, computers and vehicles.
|
Name of the company |
RUSAN PHARMA LIMITED |
||||||||||||
|
Presented By |
Canara Bank, Overseas Branch,
Nariman Point, Mumbai – 400 021 |
||||||||||||
|
1) Date and description of instrument creating the change |
20/09/1994 Hypothecation agreement for packing credit, advance dated 20th September, 1994 |
||||||||||||
|
2) Amount secured by the charge/amount owing on the securities of charge |
Rs. 15.000 millions |
||||||||||||
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
All raw materials for manufacture of Pharmaceutical formulations, tablets, injections and Bulk Drugs etc. belonging to the company and such other goods wherever stored and acceptable to the Bank as security from time to time. |
||||||||||||
|
4) Gist of the terms and conditions and extent and operation of the charge. |
To secure packing credit facility granted by the Bank to the company. Interest @ 13 % p.a. |
||||||||||||
|
5) Name and Address and description of the person entitled to the charge. |
Canara Bank, Overseas Branch, Nariman Point, Mumbai – 400 021 |
||||||||||||
|
6) Date and brief description of instrument modifying the charge |
29/04/2005 Supplemental common hypothecation agreement dated 29th April 2005 |
||||||||||||
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
By the present modification, the PC/FBE/FDB limit has been enhanced from Rs. 60.00 Millions to Rs. 90.000 millions Further the above limit of Rs. 90.000 millions shall be sacred by : Hypothecation by way of first charge as primary security on all present and future : Stock of goods meant for export such as raw material semi finished and finished goods and packing material of pharmaceuticals and other items of stock-in-trade, stores, spares goods and properties of every description wherever situated, whether at the company’s factories, place of business, godwons or in transit or wherever else or in the course of delivery. Documents of title to goods and / or goods received under their DALC and / or Book debts arising there form and all the current assets of the company Hypothecation by way of first charge as Collateral security All book debts, receivables, outstanding monies, claims, bills contracts, engagements, rights, and all other monies due and cowing to the any person, company, government or public body or authority. Air conditioners and Electrical Installations, computers, dies, equipments and tools for R & D and for QCD and other, furniture and fixture, machinery office equipments and vehicles more particularly described in Part C of Annexure II to the supplemental common hypothecator agreement dated 29th April 2005. All other terms and conditions remain unchanged. |
||||||||||||
|
|
|
||||||||||||
|
Name of the company |
RUSAN PHARMA LIMITED |
||||||||||||
|
Presented By |
Canara Bank, Overseas Branch,
Nariman Point, Mumbai – 400 021 |
||||||||||||
|
1) Date and description of instrument creating the change |
20/08/1998 Hypothecation agreement for packing credit, advance dated 29/08/1998 |
||||||||||||
|
2) Amount secured by the charge/amount owing on the securities of charge |
Rs. 2.500 millions |
||||||||||||
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
All the goods and commodities purchased, acquired, received under FLC facility such as raw materials for manufacture of Pharmaceutical Tablets, Injection and Bulk Drugs etc. of the company. All the Book debts, outstanding, money receivable, claims and bills, arising out of the sales, disposal of the goods received under FLC facility due to the company |
||||||||||||
|
4) Gist of the terms and conditions and extent and operation of the charge. |
To secure packing credit facility granted by the Bank to the company. |
||||||||||||
|
5) Name and Address and description of the person entitled to the charge. |
Canara Bank, Overseas Branch, Nariman Point, Mumbai – 400 021 |
||||||||||||
|
6) Date and brief description of instrument modifying the charge |
29/04/2005 Supplemental common hypothecation agreement dated 29th April 2005 |
||||||||||||
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
By the present modification, the PC/FBE/FDB limit has been enhanced from Rs. 40.00 Millions to Rs. 60.000 millions s given below :
Further the above limit of Rs. 60.000 millions shall be secured by : Hypothecation by way of first charge as primary security on all present and future :
Stock of goods meant for export such as raw material semi finished and finished goods and packing material of pharmaceuticals and other items of stock-in-trade, stores, spares goods and properties of every description wherever situated, whether at the company’s factories, place of business, godwons or in transit or wherever else or in the course of delivery. Documents of title to goods and / or goods received under their DALC and / or Book debts arising there form and all the current assets of the company. Hypothecation by way of first charge as Collateral security All book debts, receivables, outstanding monies, claims, bills contracts, engagements, rights, and all other monies due and cowing to the any person, company, government or public body or authority. Air conditioners and Electrical Installations, computers, dies, equipments and tools for R & D and for QCD and other, furniture and fixture, machinery office equipments and vehicles more particularly described in Part C of Annexure II to the supplemental common hypothecator agreement dated 29th April 2005. All other terms and conditions remain unchanged. |
Form 8 : As on
31.03.2007
|
Corporate
identity number (CIN) Foreign company registration number |
U24230MH1994PLC077069 |
|
Name of the
Company |
RUSAN PHARMA
LIMITED |
|
Address |
Rusan House, 58-D, Government Industrial Estate, Charkop, Kandavli (West), Mumbai – 400 067, Maharashtra, India |
|
This form is for |
Modification of
charge |
|
Type of Charge |
·
Book Debts ·
Movable
Property (Not being pledge) ·
Floating
charge |
|
Particulars of
the charge holder |
Canara Bank Overseas Branch,
211, Dalamal Tower, Nariman Point, Mumbai – 400021, Maharashtra, India |
|
Nature or description
of the instrument(s) creating or modifying the charge |
Supplemental
Common Hypothecation Agreement. |
|
Date of the
instrument creating or modifying the charge |
03.12.2007 |
|
Amount secured by
the charge |
Rs.110.000
Millions |
|
Brief particulars
of the principal terms and conditions and extent and operation of the charge |
Rate of Interest: As may be
described by the Bank from time to time. Terms of
repayment: Repayable on
demand Margin: As may be
described by the Bank from time to time. Extent and
operation of the charge: The charge is to
operate as security for the due repayment of the PC/PCFC/FDB/FBE/BRD limit
Rs.110.000 Millions ans BG/ILC/FLC limit Rs.60.000 Moillions (Which is
registered with ROC as separate charge) together with interests, additional
interest, costs, charges, expenses and all other moneys payable by the
company to the Bank in terms of sanction. |
|
Short particulars
of the property charged (including location of the property) |
Primary Security: Hypothecation by
way of first charge, of all the stocks and book debts of the company. Collateral
Security: EMT and 1st
charge on fixed assets of the company. |
|
Particular of the
present modification |
By the present modification,
the PC / PCFC / FDB / FBE/BRD limit has been enhanced from Rs.90.000 Millions
to Rs.110.000 Millions. The enhanced
limit shall be additionally security by the hypothecation of all book debts
of the company. |
|
Name of the company |
RUSAN PHARMA LIMITED |
|||||||||||||||||||||
|
Presented By |
RUSAN PHARMA LIMITED AND CANARA BANK , OVERSEAS BRANCH, NARIMAN
POINT, MUMBAI – 400021, INDIA |
|||||||||||||||||||||
|
1) Date and description of instrument creating the change |
29.08.1996 Agreements of Hypothecation
of goods and book debts dated 29th August, 1996. |
|||||||||||||||||||||
|
2) Amount secured by the charge/amount owing on the securities of charge |
Re.2.500 Millions |
|||||||||||||||||||||
|
3) Short particular of the property charged. If the property acquired is subject to charge, date of the acquired of the property should be given |
All the goods and
commodities purchased, acquired received under FLC facility such as raw
materials for manufacturer of pharmaceuticals formulations, Tablets, Injection
and Bulk Druga etc., of the company. All the book
debts, outstandings, money receivable, claims and bills, arising out of the
sales, disposal of the goods receivable under the FLC facility, due to the
company. |
|||||||||||||||||||||
|
4) Gist of the terms and conditions and extent and operation of the charge. |
To secure FLC
facility granted by the Bank to the company. |
|||||||||||||||||||||
|
5) Name and Address and description of the person entitled to the charge. |
Canara Bank Overseas Branch,
Nariman Point, Mumbai – 400021 |
|||||||||||||||||||||
|
6) Date and brief description of instrument modifying the charge |
23.09.2003 Supplemental
Common Hypothecation Agreement dated 23rd September, 2003. |
|||||||||||||||||||||
|
7) Particulars of modifications specifying the terms and conditions or the extent of operations of the charge in which modification is made and the details of the modification. |
By the present
modification, the ILC/FLC limit has been reduced from Ra.50.000 Millions to
Rs.30.000 Millions as given below: Rs. In
Millions
Further the above
limit of Rs.30.000 Millions shall be secured by :- Hypothecation by
way of first charge as primary security, on all present and future: ·
Stocks of
goods meant for export such as Raw Materials, semi finished goods, Finished goods, and
packing materials of pharmaceuticals and other iteams of stocks in trade
stores sparea, components and all other movable goods and property of very
described wherever situated whether at the company’s factories, places of
business, godown or in transit or wherever else the same may be lying or
being or in the course of delivery. ·
Documents of
title to goods and /or goods received under DALC and/or book debts arising
there from and all the current assets of the company. Hypothecation by way
of first charge as collateral security:- ·
All Book
debts reveivables, outstanding monies, claims, bills, contracts, engagements,
rights, and all other monies due and owing to the company from time to time
by any person, company, Government or public body or authority. ·
Air
Conditionsers and Electrical Installations, Computers, Dies, Equipments and
tools for R and D and for QCD and other Furniturer and Fixtures, Machinery
Office equipments and Vehicles, more particularly descibed in part C of
annexure II to the supplementaly common Hypothecation Agreement dated 23rd
September, 2003, All other terms
and conditions remain unchanged. |
Website Details Attached:
Subject research based, technologically driven Pharmaceutical Company was
established in March, 1994. Rusan is engaged in the manufacturing and exporting
of Pharmaceutical formulations, Bulk Drugs and Intermediates world-wide with a
special thrust in export to Russian Federation, CIS Countries.
Rusan's team of committed professionals with over three decades of
cumulative techno-expertise behind them have helped the company achieve its
objectives of ..
Improving Healthcare By Providing the Needs of Today.....And Tomorrow.
· Rusan's goals include:
· Customer Targeted Research and Development
· Process Upgradation and Optimization
· To Manufacture formulations using advanced technology to meet International Regulatory Standards
· To meet appropriate standards of Quality, Efficacy and Safety for all medicines.
· Technology Transfer
Products:
Detailed
Information Of The Product Will Be Available On Request To :
Rusan Pharma
Limited
58 - D,
Government Industrial Estate,
Charkop,
Kandivali(W)
Mumbai
- 400 067.
Tel No.
- ( 91 - 22 ) 868 25 12 / 868 25 15.
Fax -
91 - 22 - 868 90 56
E -
mail - rusan@bom2.vsnl.net.in
|
Product Name |
Generic Name |
Pack Size |
Size |
|
|
ANALGESIC
(OPIOID) |
||||
|
Sangesic
Injection 1 ml. |
Buprenorphine (As
hydrochloride) 0.3mg./ml. |
N.10 |
10 X 1 ML |
|
|
Sangesic
Injection 2 ml. |
Buprenorphine (As
hydrochloride) 0.3mg./ml. |
N.10 |
10 X2ML |
|
|
Sangesic Tablet |
Buprenorphine (As
hydrochloride) 0.2mg. |
N.100 |
5X20T |
|
|
Tradol Capsule |
Tramadol Hydrochloride
50 mg. |
N.20 |
1 X 20C |
|
|
Tradol Injection
1 ml. |
Tramadol
Hydrochloride 50 mg./ml. |
N.10 |
10X1 ML |
|
|
Tradol Injection
2 ml. |
Tramadol
Hydrochloride 50 mg./ml. |
N.5 |
5 X2ML |
|
|
|
|
|
|
|
|
ANALGESIC
ANTIINFLAMATORY |
||||
|
Bioran Gel 15 gm. |
Diclofenac Gel 1%
w/w |
N.1 |
1 x 15GM |
|
|
Bioran Gel 30 gm. |
Diclofenac Gel 1%
w/w |
N.1 |
1 X30GM |
|
|
Bioran Injection
3 ml. |
Diclofenac Sodium
25 mg./ml. |
N.5 |
5 X 3ML |
|
|
Bioran Rapid
Tablets |
Diclofenac Free acid
eq to Diclofenac Sodium 50mg. |
N.20 |
2 x10T |
|
|
Bioran Tablet |
Diclofenac Sodium
50 mg. |
N.100 |
10X10T |
|
|
ANTI ANEMIC, IRON
AND VITAMIN SUPPLEMENT |
||||
|
Fenotec Capsules |
Ferrous Sulphate
150 mg. (in Sastained release form) Ascorbic Acid 150 mg. Vitamin B Complex |
N.200 |
10X2X10C |
|
|
|
|
|
|
|
|
ANTI CANCER |
||||
|
Doxorubicin For
Injection (Freeze dried) |
Doxorubicin
Hydrochloride 10 mg. per vial |
N.1 |
1 X 10 MG |
|
|
Frugyl Tablet |
Flutamide 250 mg. |
N.100 |
5 X2X10T |
|
|
Methotrexate
Injection 2 ml. |
Methotrexate 25
mg./ml. |
N.10 |
10 X2ML |
|
|
Methotrexate
Injection 5 ml. |
Methotrexate 10
mg./ml. |
N.1 |
1 X 5 ML |
|
|
Methotrexate
Tablet |
Methotrexate 2.5
mg. |
N.100 |
10X10T |
|
|
Tamoxifen Citrate
Tablet USP |
Tamoxifen (As
Citrate) 10 mg. |
N.60 |
6 X10T |
|
|
|
|
|
|
|
|
ANTI EMETIC,
VOMMITING |
||||
|
Serulan Injection
2 ml. |
Metaclopramide
Hydrochloride 5 mg./ml. |
N.50 |
5X10X2ML |
|
|
Serulan Tablet |
Metaclopramide
Hydrochloride 10 mg. |
N.100 |
5X20T |
|
|
|
|
|
|
|
|
ANTI FLU,
ANTIHISTAMINIC, DECONGESTANT |
||||
|
Ephact plus Syrup |
Phenylpropanolamine
HCl BP 12.5 mg+ Chlorpheniramine Maleate BP 2 mg. Paracetamol BP 125mg. per 5
ml. |
N.1 |
1 x 100ML |
|
|
Ephact plus
Tablets |
Phenylpropanolamine
HCl BP 25 mg+ Chlorpheniramine Maleate BP 2 mg. Paracetamol BP 500mg. |
N.200 |
10X2X10T |
|
|
|
|
|
|
|
|
ANTI GLAUCOMA |
||||
|
Ocuryl 0.25% Eye
Drops 5ml. |
Timolol ( As Maleate)
0.25% w/v |
N.1 |
1 X 5 ML |
|
|
Ocuryl 0.5% Eye
Drops 5 ml. |
Timolol ( As
Maleate) 0.50% w/v |
N.1 |
1 X 5 ML |
|
|
|
|
|
|
|
|
ANTI
INFLAMMATORY |
||||
|
Prednisolone
Injection |
Prednisolone Sodium
Phosphate equivalent to prednisolone 30mg/ml |
N.3 |
3X 1 ML |
|
|
Prednisolone
Tablet |
Prednisolone 5
mg. |
N.100 |
100T |
|
|
|
|
|
|
|
|
ANTI MOTION
SICKNESS, VERTIGO |
||||
|
Cinazin Tablet |
Cinnarizine 25
mg. |
N.50 |
5X10T |
|
|
|
|
|
|
|
|
ANTI
TUBERCULOSIS |
||||
|
Ethionamide
Tablet 250mg |
Ethionamide BP
250mg |
N.50 |
5 X 10 T |
|
|
Prothionamide
Tablet |
Prothionamide
250mg |
N.50 |
5X10T |
|
|
Prothionamide
Tablet |
Prothionamide
250mg |
N.5 |
1000 T |
|
|
Pyrazinamide
Tablet |
Pyrazinamide 500
mg. |
N.100 |
10X10T |
|
|
Pyrazinamide
Tablet |
Pyrazinamide 500
mg. |
N.1 |
1000 T |
|
|
R-Butin Capsule |
Rifabutin USP
150mg |
N.30 |
2x15 C |
|
|
Rucox-4 Tablets |
Rifampicin BP 150mg,
Pyrazinamide BP 400mg, Isoniazid BP 75mg. Ethambutol HCI BP 275mg. |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
ANTIDIABETIC |
||||
|
Antibet 2.5
Tablet |
Glibenclamide 2.5
mg. |
N.100 |
5X20T |
|
|
Antibet 5 Tablet |
Glibenclamide 5
mg. |
N.100 |
5X20T |
|
|
|
|
|
|
|
|
ANTIFUNGAL |
||||
|
Funginal Cream 15
gm. |
Clotrimazole
Cream USP 1% w/w |
N.1 |
1 x 15GM |
|
|
Funginal Cream 30
gm. |
Clotrimazole
Cream USP 1% w/w |
N.1 |
1 X30GM |
|
|
Funginal V Cream
15 gm. |
Clotrimazole
Vaginal Cream USP 2% w/w |
N.1 |
1 x 15GM |
|
|
Funginal V Cream
30 gm |
Clotrimazole
Vaginal Cream USP 2% w/w |
N.1 |
1 X30GM |
|
|
Funginal V Tablet |
Clotrimazole
Vaginal Tablet USP 100 mg. |
N.6 |
1 X 6T |
|
|
|
|
|
|
|
|
ANTIHISTAMINIC,
DECONGESTANT |
||||
|
Ephact Capsules |
Phenylpropanolamine
HCI BP 50 mg.(in sustained release form) Chloropheniramine Maleate BP 8
mg.(in sustained release form) |
N.200 |
10X2X10C |
|
|
|
|
|
|
|
|
ANTIHYPERTENSIVE |
||||
|
Relsidrex-H
Tablet |
Reserpine 0.1 mg.
Dihydralazine Sulphate 10 mg. Hydrochlorothiazide 10 mg. |
N.500 |
25X20T |
|
|
|
|
|
|
|
|
ANTIMICROBIAL/ANTIBACTERIAL |
||||
|
Cefobac-500
Tablet |
Ciprofloxacin (As
hydrochloride) 500 mg. |
N.10 |
1X10T |
|
|
Cefobac Eye Drops
5 ml |
Ciprofloxacin (As
hydrochloride) 0.3% w/v |
N.1 |
1 X 5 ML |
|
|
Cefobac Infusion
100 ml |
Ciprofloxacin 200
mg./100 ml |
N.1 |
1X100 ML |
|
|
Cefobac-250
Tablet |
Ciprofloxacin (As
hydrochloride) 250 mg. |
N.10 |
1X10T |
|
|
|
|
|
|
|
|
ANTIPROTOZOAL |
||||
|
Tinisan-300
Tablet |
Tinidazole 300
mg. |
N.100 |
10X10T |
|
|
Tinisan-500
Tablet |
Tinidazole 500
mg. |
N.100 |
10X10T |
|
|
Trichazol
Infusion 100 ml. |
Metronidazole 500
mg./100 ml. |
N.1 |
1X100 ML |
|
|
Trichazol-250
Tablet |
Metronidazole 250
mg. |
N.100 |
10X10T |
|
|
Trichazol-500
Tablet |
Metronidazole 500
mg. |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
ANTIULCER |
||||
|
Gastropin
Injection 2 ml. |
Pirenzepine (As
Dihydrochloride) 10 mg./2 ml. |
N.5 |
5 X 2 ML |
|
|
Gastropin Tablet |
Pirenzepine (As Dihydrochloride)
25 mg |
N.50 |
5X10T |
|
|
Yazitin Injection
2 ml. |
Ranitidine (As
Hydrochloride) 25 mg./ml. |
N.5 |
5 X2ML |
|
|
Yazitin-150
Tablet |
Ranitidine (As
Hydrochloride) 150 mg. |
N.100 |
10X10T |
|
|
Yazitin-300
Tablet |
Ranitidine (As Hydrochloride)
300 mg. |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
ANXIOLYTIC |
||||
|
Diazepam
Injection 2 ml. |
Diazepam 5
mg./ml. |
N.10 |
10 X 2ML |
|
|
Diazepam Tablet |
Diazepam 5 mg. |
N.100 |
5X20T |
|
|
|
|
|
|
|
|
CEREBRAL
VASODILATOR |
||||
|
Nicergoline For
Injection(Freeze dried) |
Nicergoline 4mg.
per vial + Solvent for Nicergoline 4 ml. |
N.4 |
4 vials+4amps |
|
|
|
|
|
|
|
|
DERMATOLOGICAL,
ANTIBACTERIAL |
||||
|
Valoderm Cream 15
gm. |
Betamethasone (As
valerate) 0.1% w/w |
N.1 |
1 x 15GM |
|
|
Valoderm Cream 30
gm. |
Betamethasone (As
valerate) 0.1% w/w |
N.1 |
1 X30GM |
|
|
Valoderm G Cream
15 gm. |
Betamethasone (As
valerate) 0.1% w/w with Gentamycine (As Sulphate) 0.1% w/w |
N.1 |
1 x 15GM |
|
|
Valoderm G Cream
30 gm. |
Betamethasone (As
valerate) 0.1% w/w with Gentamycine (As Sulphate) 0.1% w/w |
N.1 |
1 X 30GM |
|
|
|
|
|
|
|
|
DERMATOLOGICAL,
ANTIINFLAMATORY PSORIASIS ECZEMAS |
||||
|
Cinacort Cream 15
gm. |
Triamcinolone
Acetonide cream USP 0.1%w/w |
N.1 |
1 x 15GM |
|
|
Cinacort Cream 30
gm. |
Triamcinolone
Acetonide cream USP 0.1%w/w |
N.1 |
1 X30GM |
|
|
Fluvet Cream 15
gm. |
Flumethasone
Pivalate Cream USP 0.02% w/w |
N.1 |
1 x 15GM |
|
|
Fluvet Cream 30
gm. |
Flumethasone
Pivalate Cream USP 0.02% w/w |
N.1 |
1 X30GM |
|
|
|
|
|
|
|
|
DERMATOLOGICAL,
ANTISEPTIC, ANTIMICROBIAL |
||||
|
Silvacin Cream 15
gm. |
Silversulphadiazine
1% w/w Chlorhexidine Gluconate 0.2% w/w |
N.1 |
1 x 15GM |
|
|
Silvacin Cream 30
gm. |
Silversulphadiazine
1% w/w Chlorhexidine Gluconate 0.2% w/w |
N.1 |
1 X30GM |
|
|
|
|
|
|
|
|
DIGESTIVE AID |
||||
|
Forte Enzyme
Tablet |
Pancreatin 192 mg
Hemicellulase 50mg Ox bile extract 25 mg |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
DIURETIC |
||||
|
Florix Injection 2
ml. |
Frusemide 10
mg./ml. |
N.50 |
5 X10X2ML |
|
|
Florix Tablet |
Frusemide 40 mg. |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
EXPECTORANT
MUCOLYTICS |
||||
|
Bromhexine Elixir
100 ml. |
Bromhexine
Hydrochloride 4mg./5 ml. |
N.1 |
1X100 ML |
|
|
Bromhexine Tablet
with CC |
Bromhexine
Hydrochloride 8mg. |
N.100 |
10X10T |
|
|
|
|
|
|
|
|
IMMUNOSUPRESSANT |
||||
|
R-Immun Capsule
100mg |
Cyclosporine USP
100mg |
N.50 |
10X5C |
|
|
R-Immun Capsule
25mg |
Cyclosporine USP
25mg |
N.50 |
10X5C |
|
|
R-Immun Capsule
50mg |
Cyclosporine USP
50mg |
N.50 |
10X5C |
|
Financials:
Rusan's turnover in 1995-1996 was Rs. 86.500 Millions. It was mainly due to Rusan's strength in formulation like EPHACT and FENOTEC CAPSULES that Rusan has been able to achieve a turnover of Rs. 203.200 Millions in the financial year 1997-1998
Rusan entered the new millennium with a good performance in it's sixth year of operation made a total sales of 63.70 crores out which export sales are of 603.400 Millions and local sales of 33.500 Millions.
Rusan has executed tow major export contracts during this year with the ministry of health, Russian Federation under rupee debit scheme for the supply of anti-tubercular drugs, which contributes 96% of total Rusan's turnover during 2000-2001
Infrastructure:
With the establishment of Rusan Research Centre in Mumbai, the company is rapidly emerging as a research driven enterprise with a sharply focused vision and well defined goals.
Formulation Development
The modern formulation centre has been designed for the creation of high-tech, life saving and technologically challenging pharmaceuticals
The main activities of the centre include:
· Formulation development and scale up.
· Process Upgradation and Optimization
·
Development of new drug delivery systems with a special thrust on sustained
release Systems.At the same time , The Research
·
Centre works in close cooperation with various research Institutes
in Russia.
Chemical Research
· This centre is well equipped for:
· The synthesis of new products.
· process Upgradation and Optimization
Manufacturing Facilities:
Rusan's manufacturing facility has been established in Kandla, Gujarat at a distance 792 kms to the north of Mumbai. The plant with an area of 28, 000 sq.m is located in the Kandla SPecial Economic Zone (previously Kandla Free Trade Zone)
This unit will cater to the diverse need of formulations like tablets, injections and capsules with a piloting plant facility. With an experienced manpower of 15 technical and 35 skilled workers, the plant is due to be fully operational by March' 2001.
The installed capacity of the plant is given below:
|
Goods Manufactured |
Units |
Basis |
Installed Capacity /
Year |
|
Tablets (coated /uncoated) |
Million |
Single
Shift |
370 million |
|
Capsules |
Million |
Single
Shift |
75 million |
|
Ampoules |
Million |
Single
Shift |
10 million |
|
Multidose vials |
Kilo
ltrs. |
Single
Shift |
10 million |
The plant will be equipped to manufacture various
general and specialized formulations which will comply with WHO.UK-MCA norms
and ISO 9000 norms.
Bulk Drugs:
Subject has established a sophisticated bulk drug manufacturing facility
plant at 6406, GIDC Ankaleshwar for bulk drugs and intermediates with
facilities for lab scale and scale up. This multipurpose plant with an area
2000 sq. metres has been designed to meet US FDA requirements. At present the
manpower Ankaleshwar includes 5 technical personnel and 10 skilled labour.
Subject has a very specialized range of High Cost low VolumeBulk drugs and
Intermediates.
·
Tramadol Hydrochloride
·
Buprenorphine Hydrochloride
·
Flutamide USP
·
Bisoprolol Hemifumarate
·
Oxyprenolol Hydrochloride
·
3-Aminobenzamidine 2 Hydrochloride
·
4-Nitro-3-trifluro methyl aniline
Reaction Capabilities
·
Condensation
·
Epoxidation
·
Hydrogenation
·
Cyclization
·
Esterification
·
Nitration
·
Reduction
·
Friedel Craft
·
Alkylation
Oxidation
·
Skraup
Synthesis
Chairman’s Profile:
Dr. N. Saxena did his Ph.D in Organic Chemistry from the Moscow
Friendship University.
It was
during his tenure as Head of the Unichem Research Centre (1981-1991) that the
technologies for life-saving drugs like Buprenorphine, Nifedipine, Sucralfate
were developed for the 1st time in India on a commercial scale. Thus import of
these druge in India was stopped saving valuable foreign exchange. Dr. Saxena
was also responsible for the introduction of Buprenorphine as a substitute for Morphine/Promedol/Procedol
in Russia and CIS. Incidently Dr. Saxena holds the process patent in India for
Buprenorphine.
He
started Rusan Pharma Ltd. in 1994 and in 1996 he set up a Research Centre in
the subarbs of Mumbai. This Centre is involved in development and technology
upgradation of both bulk drugs and formulations.
Awards:
In June, 1997 in recognition of his contribution to Medical Healthcare in Russia the International Academy of Sciences, one of the premier Research Institutes of Europe conferred on Dr. N. Saxena the title of “ACADEMICIAN” and presented him with the Honourable Cross of the Academy.
Dr.Saxena is not only the youngest recipient of this award, but he is also the first Indian to be so honoured.
On 29th July 1997, Dr. Navin Saxena, Chairman, Subject was honoured with the “THE INTERNATIONAL EXCELLENCE AWARD” by the Council for Small and Medium Exporters. Dr. Saxena was also awarded the “UDYOG RATTAN” by the Institute for Economic Studies for his contribution in the field of Industrial Development of India.
In addition, Subject an exporter of high quality medicines was honoured with the EXCELLENCE AWARD for excellence in Productivity, Quality, Innovation and Management.
CMT REPORT (Corruption,
Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.39.43 |
|
UK Pound |
1 |
Rs.78.34 |
|
Euro |
1 |
Rs.57.76 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
6 |
|
--PROFITABILIRY |
1~10 |
6 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
54 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|